LEADER 01048nam2-2200349---450- 001 990001721660203316 005 20050307101325.0 035 $a000172166 035 $aUSA01000172166 035 $a(ALEPH)000172166USA01 035 $a000172166 100 $a20040603f--------km-y0itay0103----ba 101 0 $afre 102 $aFR 105 $a||||||||001yy 200 1 $a<> : Aspects et problémes de la vie rurale traditionenne$fBernard Kayser 210 $aParis$cCentre de Documentasion universitaires$d[s.d.] 215 $a64$d27 cm 410 0$12001 454 1$12001 461 1$1001000172165$12001 700 1$aKAYSER,$bBernard$0129646 801 0$aIT$bsalbc$gISBD 912 $a990001721660203316 951 $aIII.1. 1625/1(I H 16)$b4304 L.M.$cI H 959 $aBK 969 $aUMA 979 $aSIAV3$b10$c20040603$lUSA01$h1035 979 $aSIAV3$b10$c20040603$lUSA01$h1038 979 $aCOPAT3$b90$c20050307$lUSA01$h1013 996 $aAspects et problémes de la vie rurale traditionenne$9947544 997 $aUNISA LEADER 02423nam 2200625 450 001 9910467218303321 005 20200520144314.0 010 $a615-5225-51-6 035 $a(CKB)4100000007803170 035 $a(OCoLC)852388076 035 $a(MdBmJHUP)muse22288 035 $a(MiAaPQ)EBC3137356 035 $a(Au-PeEL)EBL3137356 035 $a(CaPaEBR)ebr10776449 035 $a(EXLCZ)994100000007803170 100 $a20121214d2013 uy| 0 101 0 $aeng 135 $aur|||||||nn|n 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aThe village and the class war $eanti-kulak campaign in Estonia /$fAnu Mai Ko?ll 210 1$aBudapest ;$aNew York :$cCentral European University Press,$d2013. 215 $a1 online resource (298 pages) $cillustrations 225 1 $aHistorical studies in Eastern Europe and Eurasia ;$vvolume 2 311 $a615-5225-14-1 320 $aIncludes bibliographical references and index. 327 $aThe land question in Estonia -- Soviet repression as a special case of state violence -- The anti-kulak campaign -- Inventing kulaks -- Participation at the local level -- Epilogue of March 1949 -- The grammar of terror. 410 0$aHistorical studies in Eastern Europe and Eurasia ;$vv. 2. 606 $aCollectivization of agriculture$zEstonia$xHistory 606 $aCollectivization of agriculture$zSoviet Union$xHistory 606 $aState-sponsored terrorism$zEstonia$xHistory 606 $aCommunism$zEstonia$xHistory$y20th century 606 $aPeasants$zEstonia$xHistory$y20th century 606 $aCollective farms$zEstonia$xHistory 606 $aLand tenure$zEstonia$xHistory 607 $aEstonia$xRural conditions$y20th century 607 $aEstonia$xHistory$y1940-1991 608 $aElectronic books. 615 0$aCollectivization of agriculture$xHistory. 615 0$aCollectivization of agriculture$xHistory. 615 0$aState-sponsored terrorism$xHistory. 615 0$aCommunism$xHistory 615 0$aPeasants$xHistory 615 0$aCollective farms$xHistory. 615 0$aLand tenure$xHistory. 676 $a338.1/8479809044 700 $aKo?ll$b Anu Mai$01030209 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910467218303321 996 $aThe village and the class war$92447019 997 $aUNINA LEADER 04942nam 2201345z- 450 001 9910557666403321 005 20220111 035 $a(CKB)5400000000044842 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76871 035 $a(oapen)doab76871 035 $a(EXLCZ)995400000000044842 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aDrug-Drug Interactions 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (242 p.) 311 08$a3-0365-2035-X 311 08$a3-0365-2036-8 330 $aDrug-drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb-drug or food-drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions. 606 $aBiology, life sciences$2bicssc 606 $aResearch & information: general$2bicssc 610 $a(?)-sophoranone 610 $a1A2 610 $a2B6 610 $a2C19 610 $a2C8 610 $a2C9 610 $a2D6 610 $a3A4 610 $aADME 610 $aadverse drug reactions 610 $abiflavonoid 610 $achronic kidney disease 610 $acompetitive inhibition 610 $acomputational prediction 610 $aCYP 610 $aCYP1A1 610 $aCYP1A2 610 $aCYP2C9 610 $aCYP2D6 610 $aCYP3A 610 $aCYP3A4 610 $acytochrome P450 610 $acytochromes P450 610 $aDDI 610 $aDexamethasone 610 $adrug interaction 610 $adrug interactions 610 $adrug metabolism 610 $adrug transporter 610 $adrug-drug interaction 610 $adrug-drug interaction 610 $adrug-drug interactions 610 $adrug-drug interactions 610 $aexpression 610 $afexofenadine 610 $agepants 610 $ahigh plasma protein binding 610 $ain silico 610 $ain vitro 610 $ain vivo 610 $ainhibitor 610 $aixazomib 610 $aKetoconazole 610 $alasmiditan 610 $aLexicomp 610 $alow permeability 610 $aLoxoprofen 610 $amechanism-based inhibition 610 $ametabolic DDI 610 $ametabolism 610 $amigraine 610 $amonoclonal antibodies 610 $anon-competitive inhibition 610 $aO-desmethyltramadol 610 $aOATP1B1 610 $aOATP1B3 610 $aorganic anion transporting polypeptide 1A2 (OATP1A2) 610 $aP-glycoprotein (P-gp) 610 $aP450 610 $apharmacokinetics 610 $aphysiologically-based pharmacokinetics 610 $aplasma concentration 610 $apolypharmacy 610 $apotent inhibition 610 $aQSAR 610 $aregulation 610 $aRumex acetosa 610 $aselamariscina A 610 $asignal detection algorithms 610 $aspontaneous reporting systems 610 $asubset analysis 610 $asubstrate 610 $asystemic exposure 610 $atadalafil 610 $aticagrelor 610 $atissue-specific 610 $atramadol 610 $atyrosine kinase inhibitors 610 $aubiquitination 610 $auridine 5'-diphosphoglucuronosyl transferase 615 7$aBiology, life sciences 615 7$aResearch & information: general 700 $aKim$b Dong Hyun$4edt$01304704 702 $aLee$b Sangkyu$4edt 702 $aKim$b Dong Hyun$4oth 702 $aLee$b Sangkyu$4oth 906 $aBOOK 912 $a9910557666403321 996 $aDrug-Drug Interactions$93027633 997 $aUNINA